3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Sarcoma
2
Melanoma
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Anus Neoplasms
1
Adenocarcinoma
1
Interventions
pembrolizumab
24
Nivolumab
9
atezolizumab
8
Drug Therapy
6
cemiplimab
5
Immune Checkpoint Inhibitors
5
fludarabine
4
Radiotherapy
4
Paclitaxel
4
Interleukin-2
4
Cyclophosphamide
4
Docetaxel
3
fludarabine phosphate
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Radiation
2
Patient Reported Outcome Measures
2
Oncolytic Virotherapy
2
Ipilimumab
2
Immunotherapy
2
Gemcitabine
2
Filgrastim
2
Cisplatin
2
Cetuximab
2
Carboplatin
2
vocimagene amiretrorepvec
1
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
trastuzumab deruxtecan
×
Dermatologic
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled